More on PTGX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $91.41 |
|
|||
| Open | $89.96 | ||||
| 52 Wk High | $24.52 | ||||
| 52 Wk Low | $10.02 | ||||
| Day High | $92.97 | ||||
| Day Low | $87.82 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 572,369 | ||||
- Protagonist Therapeutics (PTGX) PT Raised to $95 at Goldman Sachs
- Protagonist Therapeutics (PTGX) PT Raised to $100 at Wedbush
- FDA accepts rusfertide application with priority review for blood disorder
- Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
- Protagonist Therapeutics (PTGX) PT Raised to $95 at JPMorgan
- Protagonist Therapeutics (PTGX) PT Raised to $100 at TD Cowen
- Protagonist Therapeutics (PTGX) PT Raised to $112 at Citizens: 2 Approvals This Year
- Protagonist Therapeutics (PTGX) PT Raised to $113 at Barclays
- CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- Form S-8 Protagonist Therapeutics
Entities mentioned with PTGX
- FDA | View Related Stories »
- 13G | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Earnings | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
